4-溴-2-氯溴苄 | 89720-77-4

• 物质功能分类: 有机原料 - 烃类化合物及其衍生物 - 芳香烃
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-溴-2-氯溴苄
• 中文别名: 2-氯-4-溴溴苄
• 英文名称: 4-bromo-1-bromomethyl-2-chlorobenzene
• 英文别名: 4-bromo-2-chlorobenzyl bromide；4-Bromo-1-(bromomethyl)-2-chlorobenzene
• CAS: 89720-77-4
• 化学式: C₇H₅Br₂Cl
• 分子量: 284.378
• InChiKey: DYPSDTOQOSPYOT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

安全信息

• 危险等级：
  8
• 海关编码：
  2903999090
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P260,P264,P271,P280,P301+P330+P331,P303+P361+P353,P304+P340,P305+P351+P338,P310,P363,P403+P233,P405,P501
• 危险品运输编号：
  3265
• 危险性描述：
  H335,H314
• 储存条件：
  | 2-8°C |

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Bromo-1-(bromomethyl)-2-chlorobenzene
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Bromo-1-(bromomethyl)-2-chlorobenzene
CAS number: 89720-77-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H5Br2Cl
Molecular weight: 284.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-溴-2-氯溴苄 在 sodium hydroxide 作用下， 以 乙醇 、 水 、 二甲基亚砜 为溶剂， 反应 89.0h， 生成 2-氯-4-溴苯乙酸
  参考文献：
  名称：

  ２−ピリドン化合物

  摘要：

  提供具有优良葡萄糖激酶（GK）活化作用的化合物作为药物的方法。通过式[1]表示的2-吡啶基化合物，其异构体、立体异构体，或其药学上可接受的盐，或它们的溶剂合物。（其中，R1为RA-ZA-；RA为羧基、磺基或式[5]中的任一种）【选择图】无

  公开号：

  JP2015231988A
• 作为产物：
  描述：

  4-溴-2-氯甲苯 在 N-溴代丁二酰亚胺(NBS) 、 过氧化苯甲酰 作用下， 以 四氯化碳 为溶剂， 反应 5.0h， 生成 4-溴-2-氯溴苄
  参考文献：
  名称：

  SERINE/THREONINE KINASE INHIBITORS

  摘要：

  具有公式I的化合物，其中R1、R2、R3、R4、R5、Ra、Rb、Rc、Rd、Re、n、r、s和t的定义如本文所述，并且这些化合物是PAK1的抑制剂。还公开了用于治疗癌症和过度增殖性疾病的组合物和方法。

  公开号：

  US20150031674A1
• 作为试剂：
  描述：

  4-溴-2-氯甲苯 、 N-溴代丁二酰亚胺(NBS) 、 过氧化苯甲酰 在 disodium;carbonate 、 Brine 、 hexanes 、 4-溴-2-氯溴苄 、 、 oil 作用下， 以 四氯化碳 为溶剂， 反应 18.0h， 生成 4-溴-2-氯溴苄
  参考文献：
  名称：

  Carboxyamine Compounds and Methods of Use Thereof

  摘要：

  本发明涉及使用羧酰胺化合物及其盐来治疗依赖HDAC的疾病，并用于制造治疗该类疾病的药物制剂。

  公开号：

  US20080255149A1

文献信息

• HISTONE METHYLTRANSFERASE EZH2 INHIBITOR, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF
  申请人：ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD.

  公开号：US20190345139A1

  公开（公告）日：2019-11-14

  The invention relates to a histone methyltransferase EZH2 inhibitor, a preparation method and pharmaceutical use thereof. In particular, the invention relates to a compound represented by the general formula (I), a preparation method thereof, a pharmaceutical composition containing the same, and a use thereof as a histone methyltransferase EZH2 inhibitor for treating diseases associated with the histone methyltransferase EZH2, especially cancer. The definition of each substituents in the general formula (I) is same as the definition in the specification.

  这项发明涉及一种组蛋白甲基转移酶EZH2抑制剂，其制备方法和药用。具体而言，该发明涉及一种由通式（I）表示的化合物，其制备方法，含有该化合物的药物组合物，以及将其用作组蛋白甲基转移酶EZH2抑制剂治疗与组蛋白甲基转移酶EZH2相关的疾病，特别是癌症。通式（I）中每个取代基的定义与规范中的定义相同。
• [EN] COMPOUNDS AND THEIR USE TO TREAT HISTAMINE H3 RELATED DISORDERS<br/>[FR] COMPOSÉS ET LEUR UTILISATION POUR LE TRAITEMENT DE TROUBLES ASSOCIÉS AU RÉCEPTEUR H3 DE L'HISTAMINE
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2013027001A1

  公开（公告）日：2013-02-28

  The present invention provides compounds of formula (1) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, m, n, p, q, Q1, Q2, Q3, Q4, Q5, Q6, X1, X2, X3, X4, A1 and L1, are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了式（1）的化合物及其药学上可接受的盐，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17、R18、R19、R20、m、n、p、q、Q1、Q2、Q3、Q4、Q5、Q6、X1、X2、X3、X4、A1和L1如规范中所定义，其制备方法，含有它们的药物组合物以及它们在治疗中的用途。
• NEPRILYSIN INHIBITORS
  申请人：Fleury Melissa

  公开号：US20150210690A1

  公开（公告）日：2015-07-30

  In one aspect, the invention relates to compounds having the formula I: where R 1 -R 6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

  在一个方面，该发明涉及具有以下式I的化合物： 其中R1-R6如规范中定义，或其药学上可接受的盐。这些化合物具有神经肽酶抑制活性。在另一个方面，该发明涉及包含这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。
• [EN] NEPRILYSIN INHIBITORS<br/>[FR] INHIBITEURS DE LA NÉPRILYSINE
  申请人：THERAVANCE BIOPHARMA R & D IP LLC

  公开号：WO2015116786A1

  公开（公告）日：2015-08-06

  In one aspect, the invention relates to compounds having the formula (I): where R1-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

  在一方面，本发明涉及具有公式（I）的化合物：其中R1-R6定义如说明书中所述，或其药用可接受的盐。这些化合物具有中性粒细胞弹性蛋白酶抑制活性。在另一方面，本发明涉及包含这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。
• N-benzylpiperidinol derivatives as novel USP7 inhibitors: Structure–activity relationships and X-ray crystallographic studies
  作者：Minglei Li、Shengjie Liu、Hui Chen、Xinyu Zhou、Jin Zhou、Shuxi Zhou、Haoliang Yuan、Qing-Long Xu、Jun Liu、Keguang Cheng、Hongbin Sun、Yue Wang、Caiping Chen、Xiaoan Wen

  DOI：10.1016/j.ejmech.2020.112279

  日期：2020.8

  including MDM2 and DNMT1, and thus represents a potential anticancer target. Through comparative analysis of USP7 co-crystal structures in complex with the reported piperidinol inhibitors, we noticed that the USP7 Phe409 sub-site might have good adaptability to the ligands. Based on this observation, 55 N-aromatic and N-benzyl piperidinol derivatives were designed, synthesized and biologically evaluated

  USP7作为一种去泛素酶，在调节某些癌蛋白（包括MDM2和DNMT1）的稳定性中起着重要作用，因此代表了潜在的抗癌靶标。通过对USP7共晶体结构与已报告的哌啶醇抑制剂的复合物进行比较分析，我们注意到USP7 Phe409亚位点可能对配体具有良好的适应性。基于此观察结果，设计，合成和生物学评估了55种N-芳族和N-苄基哌啶醇衍生物，其中化合物L55被鉴定为高度选择性和有效的USP7抑制剂（IC 50  = 40.8 nM，K D  = 78.3 nM）。 。X射线晶体学研究表明L55与USP7结合的新姿势与先前报道的抑制剂大不相同。细胞分析的结果表明，L55对LNCaP（IC 50  = 29.6 nM）和RS4具有很强的抗肿瘤活性。11个（IC 50  = 41.6 nM）细胞，可能是通过诱导细胞死亡并限制G0 / G1和S期。此外，L55剂量依赖性地降低了MDM2和DNMT1的蛋白质水平